University of Kentucky College of Medicine, 800 Rose St, MN 150, Lexington, KY 40536.
Department of General Surgery, Cleveland Clinic Florida, Weston, FL.
AJR Am J Roentgenol. 2021 Apr;216(4):880-893. doi: 10.2214/AJR.20.23151. Epub 2021 Feb 10.
The purpose of this study was to conduct a meta-analysis to assess the safety and efficacy of empiric embolization compared with targeted embolization in the treatment of acute upper gastrointestinal bleeding (UGIB). We searched the PubMed and Cochrane Library databases for studies performed without language restrictions from January 2000 to November 2019. Only clinical studies with a sample size of five or more were included. Clinical success, rebleeding and complication rates, survival rates, bleeding cause, embolic materials, and vessels embolized were recorded. Empiric embolization and targeted embolization (i.e., embolization performed based on angiographic evidence of ongoing bleeding) were compared when possible. Meta-analysis was performed. Among 13 included studies (12 retrospective and 1 prospective), a total of 357 of 725 patients (49.2%) underwent empiric embolization for UGIB. The clinical success rate of empiric embolization was 74.7% (95% CI, 63.1-86.3%) among the 13 studies, and the survival rate was 80.9% (95% CI, 73.8-88.0%) for 10 studies. On the basis of comparative studies, no statistically significant difference was observed between empiric and targeted embolization in terms of rebleeding rate in 111 studies (36.5% vs 29.6%; odds ratio [OR], 1.13; 95% CI, 0.77-1.65; = .53), mortality in eight studies (23.3% vs 18.0%; OR, 1.44; 95% CI, 0.89-2.33; = .14), and need for surgery to control rebleeding in four studies (17.8% vs 13.4%; OR, 1.34; 95% CI, 0.58-3.07; = .49). The pooled embolization-specific complications were 1.9% (empiric) and 2.4% (targeted). According to all available published evidence, empiric embolization assessed with endoscopic or preprocedural imaging findings (or both) appears to be as effective as targeted embolization in preventing rebleeding and mortality in patients with angiographically negative acute UGIB. Because of its favorable safety profile, empiric embolization should be considered for patients in this clinical scenario.
本研究旨在进行荟萃分析,评估经验性栓塞与靶向栓塞治疗急性上消化道出血(UGIB)的安全性和疗效。我们在无语言限制的情况下,从 2000 年 1 月至 2019 年 11 月,在 PubMed 和 Cochrane 图书馆数据库中进行了检索。仅纳入了样本量为 5 例及以上的临床研究。记录临床成功率、再出血率和并发症发生率、生存率、出血原因、栓塞材料和栓塞血管。当可能时,比较经验性栓塞和靶向栓塞(即基于血管造影显示持续出血的栓塞)。进行荟萃分析。在纳入的 13 项研究(12 项回顾性和 1 项前瞻性)中,共有 725 例患者中的 357 例(49.2%)接受了 UGIB 的经验性栓塞治疗。13 项研究中经验性栓塞的临床成功率为 74.7%(95%CI,63.1-86.3%),10 项研究的生存率为 80.9%(95%CI,73.8-88.0%)。基于比较研究,在 111 项研究中,经验性栓塞与靶向栓塞的再出血率(36.5%比 29.6%;比值比[OR],1.13;95%CI,0.77-1.65; =.53)、死亡率(23.3%比 18.0%;OR,1.44;95%CI,0.89-2.33; =.14)和控制再出血的手术需求(17.8%比 13.4%;OR,1.34;95%CI,0.58-3.07; =.49)无统计学差异。总的栓塞特异性并发症为 1.9%(经验性)和 2.4%(靶向性)。根据所有现有发表的证据,经验性栓塞(根据内镜或术前影像学发现评估,或两者兼而有之)在预防血管造影阴性的急性 UGIB 患者再出血和死亡率方面与靶向栓塞一样有效。由于其有利的安全性,对于这种临床情况的患者,应考虑经验性栓塞。